Torrent Pharmaceuticals is currently trading at Rs. 1214.00, up by 30.60 points or 2.59% from its previous closing of Rs. 1183.40 on the BSE.
The scrip opened at Rs. 1211.00 and has touched a high and low of Rs. 1216.00 and Rs. 1198.50 respectively. So far 3,712 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1334.75 on 15-Apr-2015 and a 52 week low of Rs. 569.50 on 19-May-2014.
Last one week high and low of the scrip stood at Rs. 1232.90 and Rs. 1151.25 respectively. The current market cap of the company is Rs. 20,543.00 crore.
The promoters holding in the company stood at 71.25% while Institutions and Non-Institutions held 19.02% and 9.73% respectively.
Torrent Pharmaceuticals has signed a Share Purchase Agreement (SPA) to acquire 100% stake in Zyg Pharma (Zyg Pharma), a company engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions, solutions.
Zyg Pharma is part of the Encore Group, promoted by the Merchant family and is engaged into specialty pharmaceutical business for over 50 years. The manufacturing facility is located at Pithampur, (Indore) and is approved by various regulatory authorities including US FDA, TGA Australia. The company has capabilities for on site development, analytical method development and QC laboratory with separate areas for chemical, instrumental and micro sections.
In line with its strategy to diversify into new therapy segments, the acquisition will help Torrent to strengthen its position in niche dermatological segment especially in the developed markets like US and Europe. The company has been a manufacturing partner to several international companies in India and it has also build a successful international business through partners in regulated markets as well as in emerging markets.
The company would fund the acquisition through internal accruals. The transaction has been approved by the Boards of Directors of both companies. The transaction closure is subject to customary closing conditions and requisite regulatory and other approvals, and is expected to close by August 2015.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1786.05 |
| Dr. Reddys Lab | 1210.50 |
| Cipla | 1497.50 |
| Lupin | 2106.00 |
| Zydus Lifesciences | 960.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
